Skip to main content
Please enter a legal issue and/or a location
Begin typing to search, use arrow keys to navigate, use enter to select

Find a Lawyer

More Options

Pfizer to Pay $894M to Settle Bextra, Celebrex Claims

By Admin on October 21, 2008 | Last updated on March 21, 2019

Pfizer Inc., manufacturer of Bextra and Celebrex, has agreed to pay out $894 million to settle personal injury suits and other legal tangles involving the two pain medications.

Bextra, a non-steroidal anti-inflammatory (NSAID) pain medication, was pulled from the market in 2005. Celebrex, another NSAID, continues to be a top seller for Pfizer. Reuters reports that the $894 in settlements (announced Thursday) will be distributed as follows: $745 million to settle personal injury cases related to Bextra and Celebrex; $60 million to settle with 33 states and the District of Columbia over the marketing of Bextra; and $89 million toward resolution of consumer fraud class actions over potential financial harm caused by the promotion of the two drugs. According to Forbes, "the decision to settle follows a string of litigation that found in favor of Pfizer in federal and New York State courts over claims that Celebrex caused heart attacks and strokes in patients."

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.

Or contact an attorney near you:
Copied to clipboard